Provided by Tiger Trade Technology Pte. Ltd.

Aldeyra Therapeutics

5.53
+0.44008.64%
Post-market: 5.42-0.1100-1.99%18:22 EST
Volume:974.06K
Turnover:5.35M
Market Cap:332.70M
PE:-7.67
High:5.61
Open:5.21
Low:5.15
Close:5.09
52wk High:7.20
52wk Low:1.14
Shares:60.16M
Float Shares:48.48M
Volume Ratio:1.52
T/O Rate:2.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7210
EPS(LYR):-0.9389
ROE:-64.31%
ROA:-28.94%
PB:6.76
PE(LYR):-5.89

Loading ...

Analysts Conflicted on These Healthcare Names: Arcturus Therapeutics (ARCT), Newron Pharmaceuticals SpA (OtherNWPHF) and Aldeyra Therapeutics (ALDX)

TIPRANKS
·
Jan 21

ATA Creativity Global Among 3 Promising Penny Stocks

Simply Wall St.
·
Jan 20

Aldeyra Therapeutics Chief Development Officer Stephen Machatha to Resign

MT Newswires Live
·
Jan 02

Aldeyra Therapeutics Grants $88,000 Transition Bonus to Departing Chief Development Officer

Reuters
·
Jan 01

Aldeyra Shares Fall Premarket After FDA Extends Reproxalap Review

Dow Jones
·
Dec 16, 2025

Aldeyra Therapeutics Shares Drop 14.3% Premarket After Pdufa Extension of Its Drug Candidate for Dry Eye Disease Treatment

THOMSON REUTERS
·
Dec 16, 2025

BRIEF-Aldeyra Therapeutics Announces PDUFA Extension Of The New Drug Application Of Reproxalap For The Treatment Of Dry Eye Disease

Reuters
·
Dec 16, 2025

Aldeyra Therapeutics Announces Pdufa Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease

THOMSON REUTERS
·
Dec 16, 2025

Aldeyra Therapeutics Inc - Extended Pdufa Target Action Date Is March 16, 2026

THOMSON REUTERS
·
Dec 16, 2025

Aldeyra Therapeutics Showcases Broad Immunology Pipeline Targeting Immune-Mediated Diseases in New R&D Presentation

Reuters
·
Nov 13, 2025

BRIEF-Aldeyra Therapeutics Announces Expansion of RASP Platform

Reuters
·
Nov 13, 2025

Aldeyra Therapeutics Reports Positive Preclinical Results for ADX-248 in Neurological Disease Models

Reuters
·
Nov 13, 2025

Aldeyra Therapeutics Announces Expansion of Rasp Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

THOMSON REUTERS
·
Nov 13, 2025

Aldeyra Therapeutics to Join Jefferies Global Healthcare Conference in London

Reuters
·
Nov 11, 2025

Aldeyra Therapeutics Price Target Maintained With a $9.00/Share by BTIG

Dow Jones
·
Nov 10, 2025

Aldeyra Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
Nov 04, 2025

High Growth Tech Stocks In The US Market With Promising Potential

Simply Wall St.
·
Oct 29, 2025

Aldeyra ADX-629 achieves statistically significant improvement in liver function

TIPRANKS
·
Oct 28, 2025

Aldeyra Therapeutics Reports Positive Phase 2 Results for ADX-629 in Alcohol-Associated Hepatitis

Reuters
·
Oct 28, 2025

Aldeyra Therapeutics Inc - Adx-629 Shows Significant Improvement in Liver Function

THOMSON REUTERS
·
Oct 28, 2025